Medicilon(SH:688202) Zheng Quan Zhi Xing·2025-08-29 17:01Core Viewpoint - The Shanghai Medicilon Inc. has received approval from its Board of Directors' Compensation and Assessment Committee for its 2025 Restricted Stock Incentive Plan, indicating compliance with relevant laws and regulations [1][4]. Summary by Sections Compliance with Regulations - The company confirms that there are no prohibitive circumstances under the relevant laws and regulations for implementing the stock incentive plan, including the Company Law and Securities Law [2][3]. - The plan's initial grant recipients meet the qualifications set forth in the Company Law, Securities Law, and other relevant regulations [3][4]. Incentive Plan Details - The initial grant recipients are core employees of the company and its subsidiaries, excluding independent directors and supervisors, ensuring compliance with the incentive object conditions [3][4]. - The plan's formulation, review process, and content adhere to the legal requirements, and the granting arrangements do not infringe on the interests of the company and its shareholders [4]. Governance and Objectives - The implementation of the incentive plan is expected to enhance the company's governance structure, attract and retain talent, and align the interests of shareholders, the company, and the core team [4].